Avacta Group Gestione

Gestione criteri di controllo 1/4

Avacta Group Il CEO è Chris Coughlin, nominato in May2024, ha un mandato di meno di un anno. possiede direttamente 0.014% delle azioni della società, per un valore di € 28.78K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.7 anni e 0.4 anni.

Informazioni chiave

Chris Coughlin

Amministratore delegato

UK£53.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.01%
Durata media del management	1.7yrs
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Chris Coughlin (54 yo)

less than a year

Mandato

UK£53,000

Compensazione

Dr. Christina M. Coughlin, also known as Chris, BS, MD, PH D., was Head of Research and Development of Avacta Group Plc from February 1, 2024 and serves as its Chief Executive Officer from May 01, 2024 and...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christina Coughlin	CEO, Interim Chief Medical Officer and Director	less than a year	UK£53.00k	0.014% € 28.8k
Tony Gardiner	CFO & Company Secretary	8.8yrs	UK£409.00k	0.0022% € 4.7k
Michelle Morrow	Chief Scientific Officer	no data	Nessun dato	Nessun dato
Emma Wright	Group In-House Counsel	no data	Nessun dato	Nessun dato
Michael Vinegrad	Group Communications Director	3.8yrs	Nessun dato	Nessun dato
R. Slater	Chief Operating Officer of Diagnostics	8.3yrs	UK£69.00k	Nessun dato
David Wilson	Chief Commercial Officer of Diagnostics	1.8yrs	Nessun dato	Nessun dato
Karen Harrison	Chief Operating Officer of Therapeutics Division	1.7yrs	Nessun dato	Nessun dato
Anne McGurk	Joint Managing Director of Launch Diagnostics	1.6yrs	Nessun dato	Nessun dato
Ian Jones	Joint Managing Director of Launch Diagnostics	1.6yrs	Nessun dato	Nessun dato
Simon Bennett	Chief Business Officer of Therapeutics	less than a year	Nessun dato	Nessun dato
Sebastien Goenen	Chief Operating Officer of Coris BioConcept	1.7yrs	Nessun dato	Nessun dato

1.7yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di RTQ1 non è considerato esperto (durata media 1.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christina Coughlin	CEO, Interim Chief Medical Officer and Director	2.7yrs	UK£53.00k	0.014% € 28.8k
Trevor Nicholls	Independent Non-Executive Director	11.3yrs	UK£47.00k	0.029% € 61.8k
Darlene Deptula-Hicks	Non Executive Director	less than a year	Nessun dato	Nessun dato
Shaun Chilton	Non-Executive Independent Chairman	1.4yrs	UK£26.00k	0.011% € 23.0k
Mark A. Goldberg	Independent Non-Executive Director	3.3yrs	UK£53.00k	Nessun dato
Paul Fry	Independent Non-Executive Director	4.8yrs	UK£47.00k	Nessun dato
Alan Ho	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
William Tap	Chairman of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Robert Metcalf	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Andrea Napolitano	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Lee Cranmer	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Anthony Yu	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato

0.4yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di RTQ1 non è considerato esperto (durata media del mandato 0.4 anni), il che suggerisce un nuovo consiglio.

Avacta Group Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Recent updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

First half 2024 earnings released: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)

New major risk - Financial position

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Full year 2023 earnings released: UK£0.091 loss per share (vs UK£0.15 loss in FY 2022)

New minor risk - Financial data availability

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.036 loss in 1H 2022)

New major risk - Financial position

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

New major risk - Share price stability

New major risk - Share price stability

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Full year 2022 earnings released: UK£0.15 loss per share (vs UK£0.11 loss in FY 2021)

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

High number of new and inexperienced directors

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

First half 2022 earnings released: UK£0.036 loss per share (vs UK£0.041 loss in 1H 2021)

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

High number of new and inexperienced directors

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Less than half of directors are independent

Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.084 loss in FY 2020)

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.037 loss in 1H 2020)

Avacta Group Plc Announces Pre-Clinical Development Milestone in LG Chem Life Sciences Partnership

Avacta Group plc Provides Update on AffiDX Lateral Flow Test

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

MHRA Confirms Registration of Avacta’s Affidx® SARS-CoV-2 Antigen Lateral Flow Test

Avacta Group plc Provides an Update on Lateral Flow Test Regulatory Submissions

Full year 2020 earnings released: UK£0.084 loss per share (vs UK£0.092 loss in FY 2019)

Full year 2020 earnings released: UK£0.084 loss per share (vs UK£0.092 loss in FY 2019)

Avacta Signs Diagnostic Licensing Deal with Biokit

Avacta Group plc Announces its AffiDX SARS-CoV-2 Rapid Antigen Lateral Flow Test Detects the Dominant New Variants of the Coronavirus

Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 Approved by MHRA